Rodolfo Hrosz has chosen to step down from his position as Managing Director of the company, effective April 30. He will be ...

Denosumab works by specifically targeting the RANK ligand (RANKL), a critical protein in the lifecycle of osteoclasts, the ...

As per the company, the drug functions by blocking a protein called RANKL, which is responsible for breaking down bone tissue ...

Infosys, BHEL, Sun Pharma, NBCC (India), Bharti Hexacom, Eternal, Aurobindo Pharma and TARC will be in the spotlight on ...

Stocks like TARC, Bharti Hexacom, Infosys, Aurobindo Pharma, Bharat Heavy Electricals, Bank of India, Tata Steel, Sanofi ...

As Fierce Pharma points out, patent expirations are a routine occurrence in the pharmaceutical world, but 2025 stands out for ...

Denosumab works by specifically targeting the RANK ligand (RANKL), a critical protein in the lifecycle of osteoclasts, the ...

Celltrion gains Australian approval for three biosimilars in ophthalmology and bone disease Celltrion secures TGA endorsement ...

Accord received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use for ...

The study explores whether Prolia/Xgeva (denosumab), a widely used therapy for osteoporosis and bone tumors, can regenerate ...

Amneal Pharmaceuticals (AMRX) announced that three large insurance coverage accounts, the Veterans Administration, UnitedHealthcare (UNH) and ...

On March 5, 2025, the FDA cleared an investigational new drug application for CTD402, a CD7-targeted universal CAR T-cell therapy, for the treatment of pediatric and adult patients with ...